Phase IV 4 Way Crossover Study to Assess and Compare the Effect of a Single Nighttime Administration of Zolpidem, Silenor and Placebo on Arousability, Ataxia/Balance and Cognitive Performance in Healthy Volunteers.
Phase of Trial: Phase IV
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Doxepin (Primary) ; Zolpidem
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Pernix Therapeutics Holdings
- 16 Jun 2016 Primary endpoint has been met. (Auditory Arousal Threshold (AAT) at t-max), as reported in a Pernix Therapeutics media release.
- 16 Jun 2016 According to a Pernix Therapeutics media release, results from this study were presented at the SLEEP 2016 International meeting.
- 16 Jun 2016 Status changed from recruiting to completed, according to a Pernix Therapeutics media release.